Status:
TERMINATED
ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing
Lead Sponsor:
Invitae Corporation
Collaborating Sponsors:
Eastern Cooperative Oncology Group
Conditions:
Pancreatic Adenocarcinoma
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study includes participants with pancreatic cancer who are undergoing genetic testing at Invitae related to their diagnosis of pancreatic cancer. Our goal in this study is two-fold. First, we wo...
Detailed Description
Patients will be contacted for patient outcomes survey completion at months: 1, 4, 8, 12, 18, 24, 30, 36, 42, 48, 54, and 60. Patients will also be contacted for survival collection every 6 months dur...
Eligibility Criteria
Inclusion
- Patient has consented to germline genetic testing
- Patient has a histologically confirmed diagnosis of pancreatic cancer
- Patient has undergone or is planned to undergo surgical resection with curative intent
- Patient is willing to allow collection of a tissue sample from surgical resection
- Patient is willing to provide research blood samples (every 6 months for 2 years)
- Patient must be at least 18 years of age
Exclusion
- Patient has evidence of metastatic or recurrent pancreatic cancer at time of consent
- Patient is unable to consent.
Key Trial Info
Start Date :
August 23 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 6 2022
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT05380557
Start Date
August 23 2021
End Date
September 6 2022
Last Update
December 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Invitae SF
San Francisco, California, United States, 94103